Search Results - "Alexander, Sherry"

A meta-epidemiological analysis of post-hoc comparisons and primary endpoint interpretability among randomized noncomparative trials in clinical medicine by Sherry, Alexander D., Msaouel, Pavlos, Ludmir, Ethan B.

“…Randomized noncomparative trials (RNCTs) promise reduced accrual requirements vs randomized controlled comparative trials because RNCTs do not enroll a control…”
Get full text

Challenges, Complexities, and Considerations in the Design and Interpretation of Late-Phase Oncology Trials by Lin, Timothy A., Sherry, Alexander D., Ludmir, Ethan B.

“…Optimal management of cancer patients relies heavily on late-phase oncology randomized controlled trials. A comprehensive understanding of the key…”
Get full text

Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial by Tang, Chad, Sherry, Alexander D, Haymaker, Cara, Bathala, Tharakeswara, Liu, Suyu, Fellman, Bryan, Cohen, Lorenzo, Aparicio, Ana, Zurita, Amado J, Reuben, Alexandre, Marmonti, Enrica, Chun, Stephen G, Reddy, Jay P, Ghia, Amol, McGuire, Sean, Efstathiou, Eleni, Wang, Jennifer, Wang, Jianbo, Pilie, Patrick, Kovitz, Craig, Du, Weiliang, Simiele, Samantha J, Kumar, Rachit, Borghero, Yerko, Shi, Zheng, Chapin, Brian, Gomez, Daniel, Wistuba, Ignacio, Corn, Paul G

“…Despite evidence demonstrating an overall survival benefit with up-front hormone therapy in addition to established synergy between hormone therapy and…”
Get more information

Lost in the plot: missing visual elements in Kaplan-Meier plots of phase III oncology trials by Sherry, Alexander D, Msaouel, Pavlos, Kouzy, Ramez, Abi Jaoude, Joseph, Lin, Timothy A, Taniguchi, Cullen M, Fuller, Clifton David, Minsky, Bruce, Ludmir, Ethan B

“…Missing visual elements (MVE) in Kaplan-Meier (KM) curves can misrepresent data, preclude curve reconstruction, and hamper transparency. This study evaluated…”
Get full text

Systemic Inflammation After Radiation Predicts Locoregional Recurrence, Progression, and Mortality in Stage II-III Triple-Negative Breast Cancer by Sherry, Alexander D., von Eyben, Rie, Newman, Neil B., Gutkin, Paulina, Mayer, Ingrid, Horst, Kathleen, Chakravarthy, A. Bapsi, Rafat, Marjan

“…Patients with triple-negative breast cancer experience high rates of recurrence after radiation, which may be facilitated by the recruitment of circulating…”
Get full text

Prevalence, trends, and characteristics of trials investigating local therapy in contemporary phase 3 clinical cancer research by Sherry, Alexander D, Corrigan, Kelsey L, Kouzy, Ramez, Jaoude, Joseph Abi, Yang, Yumeng, Patel, Roshal R, Totten, Douglas J, Newman, Neil B, Das, Prajnan, Taniguchi, Cullen, Minsky, Bruce, Snyder, Rebecca A, Fuller, C David, Ludmir, Ethan

“…Although most patients with cancer are treated with local therapy (LT), the proportion of late-phase clinical trials investigating local therapeutic…”
Get full text

Metastases-Targeting Radiotherapy and ADT-Reply by Sherry, Alexander D, Corn, Paul G, Tang, Chad

Get more information

Residency Interviews in Radiation Oncology After COVID-19: Perspectives From Recently Matched Applicants by Sherry, Alexander D., Rooney, Michael K., Bernard, Vincent, Seo, Aaron, Marqueen, Kathryn E., Schrank, Benjamin R.

Get full text

Systemic inflammatory dynamics during chemoradiotherapy predict response, relapse, metastasis, and survival in esophageal carcinoma by Sherry, Alexander D., Newman, Neil B., Anderson, Joshua L., Osmundson, Evan C.

“…Background and Objectives Lymphopenia associated with chemoradiotherapy predicts prognosis in esophageal carcinoma. The purpose of our study was to evaluate…”
Get full text

Feasibility and Tolerability of Adjuvant Capecitabine-Based Chemoradiation in Patients With Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy: A Prospective Clinical Trial by Balbach, Meridith L., Sherry, Alexander D., Rexer, Brent N., Abramson, Vandana G., Niermann, Kenneth J., Johnson, Corbin R., Park, Ben Ho, Mayer, Ingrid A., Chakravarthy, A. Bapsi

“…Addition of adjuvant capecitabine improves overall survival for patients with breast cancer lacking pathologic complete response to standard-of-care…”
Get full text

Mean cardiopulmonary dose and vertebral marrow dose differentially predict lineage-specific leukopenia kinetics during radiotherapy for esophageal cancer by Anderson, Joshua L., Newman, Neil B., Anderson, Chelsea, Sherry, Alexander D., Yock, Adam D., Osmundson, Evan C.

“…•Hematologic toxicity is known to predict poor outcomes in esophageal cancer (EC).•Off-target radiation during treatment for EC predicts lineage-specific…”
Get full text

Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND by Sherry, Alexander D., Bathala, Tharakeswara K., Liu, Suyu, Fellman, Bryan M., Chun, Stephen G., Jasani, Nikesh, Guadagnolo, B. Ashleigh, Jhingran, Anuja, Reddy, Jay P., Corn, Paul G., Shah, Amishi Y., Kaiser, Kelsey W., Ghia, Amol J., Gomez, Daniel R., Tang, Chad

“…The benefit of local consolidative therapy (LCT) for oligometastasis across histologies remains uncertain. EXTernal beam radiation to Eliminate Nominal…”
Get full text

In Reply: A Retrospective Cohort Study of Longitudinal Audiologic Assessment in Single and Fractionated Stereotactic Radiosurgery for Vestibular Schwannoma by Khattab, Mohamed H, Sherry, Alexander D, Cmelak, Anthony J, Attia, Albert

Get full text

Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase III oncology trials by Sherry, Alexander D, Lin, Timothy A, McCaw, Zachary R, Beck, Esther J, Kouzy, Ramez, Abi Jaoude, Joseph, Passy, Adina H, Miller, Avital M, Kupferman, Gabrielle S, Fuller, Clifton David, Thomas, Jr, Charles R, Koay, Eugene J, Tang, Chad, Msaouel, Pavlos, Ludmir, Ethan B

“…Disease progression in clinical trials is commonly defined by radiologic measures. However, clinical progression may be more meaningful to patients, may occur…”
Get full text

Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 Fallacy by Sherry, Alexander D., Msaouel, Pavlos, McCaw, Zachary R., Abi Jaoude, Joseph, Hsu, Eric J., Kouzy, Ramez, Patel, Roshal, Yang, Yumeng, Lin, Timothy A., Taniguchi, Cullen M., Rödel, Claus, Fokas, Emmanouil, Tang, Chad, Fuller, Clifton David, Minsky, Bruce, Meirson, Tomer, Sun, Ryan, Ludmir, Ethan B.

“…The ‘Table 1 Fallacy’ refers to the unsound use of significance testing for comparing the distributions of baseline variables between randomised groups to draw…”
Get full text

Off-Protocol Radiation Therapy in Phase 3 Metastatic Solid Tumor Trials by Sherry, Alexander D., Lin, Timothy A., McCaw, Zachary R., Beck, Esther J., Kouzy, Ramez, Abi Jaoude, Joseph, Passy, Adina H., Miller, Avital M., Kupferman, Gabrielle S., Fuller, Clifton David, Thomas, Charles R., Koay, Eugene J., Tang, Chad, Msaouel, Pavlos, Ludmir, Ethan B.

“…Increasing data suggest that radiation therapy, particularly ablative radiation therapy, alters the natural history of metastatic disease. For patients with…”
Get full text

Noninvasive Thalamotomy for Refractory Tremor by Frameless Radiosurgery by Khattab, Mohamed H., Cmelak, Anthony J., Sherry, Alexander D., Luo, Guozhen, Wang, Li, Yu, Hong, Hedera, Peter, Phibbs, Fenna T., Lindsell, Christopher J., Neimat, Joseph, Kirschner, Austin N.

“…We sought to determine whether a more widely accessible, noninvasive, frameless approach to radiosurgical thalamotomy would improve objective measures of…”
Get full text

Noninvasive Capsulotomy for Refractory Depression by Frameless Stereotactic Radiosurgery by Khattab, Mohamed H., Sherry, Alexander D., Devan, Sean P., Luo, Guozhen, Chaballout, Basil H., Jean-Baptiste, Samuel, Xu, Junzhong, Bick, Sarah, Petrie, William M., Cmelak, Anthony J.

“…Effective treatment options for refractory depression are needed. Recent advancements permit both precise ablative radiation and functional neurologic…”
Get full text

The birth, decline, and contemporary re-emergence of endovascular brachytherapy for prevention of in-stent restenosis by Khattab, Mohamed H., Sherry, Alexander D., Barker, Colin M.

“…Despite the advent of drug-eluting stents and dual antiplatelet therapy in the interventional management of cardiovascular disease, restenosis rates remain…”
Get full text

Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation by Lin, Timothy A, McCaw, Zachary R, Koong, Alex, Lin, Christine, Abi Jaoude, Joseph, Patel, Roshal, Kouzy, Ramez, El Alam, Molly B, Sherry, Alexander D, Noticewala, Sonal S, Fuller, Clifton D, Thomas, Jr, Charles R, Sun, Ryan, Lee, J Jack, Lin, Ruitao, Yuan, Ying, Shyr, Yu, Meirson, Tomer, Ludmir, Ethan B

“…Survival analyses of novel agents with long-term responders often exhibit differential hazard rates over time. Such proportional hazards violations (PHV) may…”
Get full text